Dashboard
Manage Tickers

LTRN


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

lantern-pharma-to-showcase-two-of-its-commercially-deployed-ai-research-platforms-at-the-inaugural-ai-for-biology-and-medicine-symposium-at-the-university-of-north-texas
Lantern Pharma To Showcase Two Of Its Comm...
10/30/2025 12:11:49

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from ...

lantern-pharma-presents-clinical-data-from-ongoing-phase-1-trial-of-lp-284-at-llm-congress-featuring-metabolic-response-in-aggressive-dlbcl-case-after-multiple-failed-therapies
Lantern Pharma Presents Clinical Data From...
10/28/2025 12:51:06

AI-advanced drug candidate achieves complete metabolic response after two cycles in patient who failed CAR-T and bispecific ant...

watching-lantern-pharma-shares-move-higher-traders-circulate-fda-news-reported-september-16-2025
Watching Lantern Pharma; Shares Move Highe...
09/30/2025 20:25:38

trading-halt-halt-status-updated-at-84000-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 8:40:...
09/16/2025 12:40:07

lantern-pharmas-lp-184-meets-all-phase-1a-endpoints-shows-clinical-benefit-in-hard-to-treat-cancers-and-advances-to-phase-2-trials
Lantern Pharma's LP-184 Meets All Phase 1a...
09/16/2025 12:30:30

LP-184 achieves all primary endpoints and demonstrates a favorable safety and tolerability profile positioning it for both mono...

trading-halt-halted-at-82500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 8:25:00 a.m. ET - ...
09/16/2025 12:25:27

lantern-pharma-says-fda-confirms-potential-incorporation-of-spironolactone-as-combination-agent-in-trial-plans-ind-amendment-submission--trial-initiation-for-pediatric-cns-cancer-trial-in-q1-2026
Lantern Pharma Says FDA Confirms Potential...
09/03/2025 13:51:15

lantern-pharma-completes-type-c-meeting-with-fda-advancing-pediatric-cns-cancer-trial-including-atypical-teratoid-rhabdoid-tumor
Lantern Pharma Completes Type C Meeting Wi...
09/03/2025 13:47:13

Lantern Pharma Inc. (NASDAQ:LTRN), an AI-driven clinical -stage oncology company developing targeted therapies for cancer that ...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
08/14/2025 21:06:20

lantern-pharma-q2-eps-040-beats-048-estimate
Lantern Pharma Q2 EPS $(0.40) Beats $(0.48...
08/13/2025 20:36:00

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48...

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
08/11/2025 21:06:28

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
08/07/2025 12:07:31

lantern-pharmas-starlight-therapeutics-receives-fda-clearance-its-ind-for-phase-ib2a-glioblastoma-multiforme-trial
Lantern Pharma's Starlight Therapeutics Re...
08/06/2025 12:32:51

Novel combination therapy with STAR-001 targets the most aggressive and deadliest forms of brain cancer at first progressionGBM...

lantern-pharma-unveils-predictbbbai-with-94-accuracy-revolutionizing-cns-drug-development-through-real-time-ai
Lantern Pharma Unveils PredictBBB.ai With ...
08/04/2025 12:56:34

Industry-Leading Platform Achieves 94% Accuracy with Real-Time Machine Learning, Providing Open-Access to Critical CNS Drug Dev...

lantern-pharma-completes-early-enrollment-in-japan-for-lung-cancer-trial-targeting-never-smokers
Lantern Pharma Completes Early Enrollment ...
07/31/2025 11:35:14

Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its propr...

lantern-pharma-reports-complete-metabolic-response-in-a-heavily-pre-treated-lymphoma-patient-with-lp-284-in-its-phase-1-clinical-trial
Lantern Pharma Reports Complete Metabolic ...
07/23/2025 11:58:59

AI-guided, synthetic lethal therapy achieves complete metabolic response after just two cycles in patient who failed three prio...

lantern-pharma-secures-eu-patent-allowance-for-lp-284-expanding-global-ip-for-b-cell-lymphoma-therapy
Lantern Pharma Secures EU Patent Allowance...
07/21/2025 12:21:36

The EU patent allowance strengthens the prior patent allowance for LP-284 in the US, Japan India and Mexico.LP-284 has the pote...

lantern-pharma-launches-ai-module-trained-on-221-clinical-trials-to-predict-efficacy-of-dna-damaging-agent-combinations-platform-already-guided-fda-cleared-phase-1b2-trial-in-triple-negative-breast-cancer
Lantern Pharma Launches AI Module Trained ...
07/15/2025 13:42:50

The AI module, trained on 221 clinical trials, will be incorporated as part of Lantern's AI platform, RADR ®, and will init...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/08/2025 12:07:32

lantern-pharma-enters-1553m-at-the-market-offering-agreement-with-thinkequity
Lantern Pharma Enters $15.53M At-The-Marke...
07/03/2025 20:14:05

On July 3, 2025, Lantern Pharma Inc., a Delaware corporation (the "Company"), entered into an ATM Sales Agreement (the ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION